

Pursuant to the provisions of article 228 of the Consolidated Text of the Securities Market Act, approved by the Legislative Royal Decree 4/2015, of 23 October, Grifols, S.A. ("**Grifols**") hereby informs about the following

RELEVANT EVENT

Grifols S.A. (Grifols) informs about the sale of the companies Biotest US Corporation and Haema AG ("**Biotest**" and "**Haema**", respectively) to Scranton Enterprises B.V. ("**Scranton**") for the global amount of \$537 million. Scranton is an existing shareholder of Grifols.

Grifols acquired Haema on June 4, 2018 and Biotest on August 1, 2018 for an amount of €220 million and \$286 million, respectively.

The current sale of Biotest and Haema to Scranton is taking place for the same price, at the current \$/€ exchange rate, and with the same terms and conditions existing when Grifols acquired both companies.

Grifols will have a call option over all the shares of the companies sold to Scranton, and the ability to repurchase them at any time after the first year anniversary.

The current plasma supply agreements have been extended to a 30-year period, ensuring that all plasma collected by Biotest and Haema continues to be supplied to Grifols.

In Barcelona, on December 31, 2018

Nuria Martín Barnés
Secretary to the Board of Directors